Publication Name	World Journal of Clinical Oncology
Manuscript ID	86098
Country	China

Received	2023-06-01 08:06
Peer-Review Started	2023-06-01 08:07
To Make the First Decision
Return for Revision	2023-08-16 06:11
Revised	2023-09-05 03:05
Second Decision	2023-11-13 00:55
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief	2023-11-17 07:16
Articles in Press	2023-11-17 07:16
Publication Fee Transferred
Edit the Manuscript by Language Editor	2023-11-06 17:20
Typeset the Manuscript	2023-12-18 09:09
Publish the Manuscript Online	2023-12-22 03:31

ISSN	2218-4333 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Oncology
Manuscript Type	Retrospective Study
Article Title	Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy
Manuscript Source	Unsolicited Manuscript
All Author List	Ning Wang, Fei-Li Chen, Lu Pan, Yan Teng, Xiao-Juan Wei, Han-Guo Guo, Xin-Miao Jiang, Ling Huang, Si-Chu Liu, Zhan-Li Liang and Wen-Yu Li
Funding Agency and Grant Number
Corresponding Author	Wen-Yu Li, Doctor, Chief Doctor, School of Medicine, South China University of Technology, No. 123 Huifu West Road, Guangdong 510006, Guangdong Province, China. lwy80411@163.com
Key Words	Zanubrutinib; High-dose methotrexate; Primary central nervous system lymphoma; Liquid biopsy; Circulating tumor DNA
Core Tip	Zanubrutinib combined with high-dose methotrexate provided a marked clinical response and tolerance in newly diagnosed primary central nervous system lymphoma patients. Additionally, the detection of circulating tumor DNA in cerebrospinal fluid played a significant part in disease surveillance and treatment response monitoring. However, given the small sample size and retrospective nature of this study, further research is required to validate our findings.
Publish Date	2023-12-22 03:31
Citation	Wang N, Chen FL, Pan L, Teng Y, Wei XJ, Guo HG, Jiang XM, Huang L, Liu SC, Liang ZL, Li WY. Clinical outcomes of newly diagnosed primary central nervous system lymphoma treated with zanubrutinib-based combination therapy. World J Clin Oncol 2023; 14(12): 606-619
URL	https://www.wjgnet.com/2218-4333/full/v14/i12/606.htm
DOI	https://dx.doi.org/10.5306/wjco.v14.i12.606

Full Article (PDF)	WJCO-14-606-with-cover.pdf
Full Article (Word)	WJCO-14-606.docx
Manuscript File	86098_Auto_Edited-JRF-Webster J-JLW.docx
Answering Reviewers	86098-Answering reviewers.pdf
Audio Core Tip	86098-Audio core tip.m4a
Biostatistics Review Certificate	86098-Biostatistics statement.pdf
Conflict-of-Interest Disclosure Form	86098-Conflict-of-interest statement.pdf
Copyright License Agreement	86098-Copyright license agreement.pdf
Signed Informed Consent Form(s) or Document(s)	86098-Informed consent statement.pdf
Institutional Review Board Approval Form or Document	86098-Institutional review board statement.pdf
Non-Native Speakers of English Editing Certificate	86098-Language certificate.pdf
Peer-review Report	86098-Peer-review(s).pdf
Scientific Misconduct Check	86098-Bing-Fan JR-2.png
Scientific Editor Work List	86098-Scientific editor work list.pdf